CDC25C抗体在肝病患者中的血清学检测

Serological analysis of anti-CDC25C antibody in human liver diseases

目的:探讨细胞分裂周期蛋白25同源蛋白C(cell division cycle 25 C,CDC25C)抗体在肝病患者血清中出现的情况及临床意义.方法:选取经病理诊断证实的肝细胞癌(hepatocellular carcinoma,HCC)患者血清61例、肝硬化患者血清45例、病毒性乙型肝炎患者血清61例和正常人血清61例,通过酶联免疫吸附实验(enzyme-linked immunosorbent assay,ELISA)方法,对上述血清进行CDC25C抗体定量检测,并运用统计学方法分析和探讨CDC25C在肝病发展中的作用.结果:ELISA显示HCC患者血清中的CDC25C抗体的阳性率显著高于肝硬化患者血清、病毒性乙型肝炎患者血清和正常人血清(P<0.05).经两两比较,正常人血清组中的CDC25C抗体阳性率均低于其他组(P<0.05),而在肝硬化患者组和病毒性乙型肝炎患者组之间没有显著性差异(P>0.05).结合临床参数指标分析,发现CDC25C抗体的阳性率与HCC患者的年龄、性别、黄疸程度及谷丙转氨酶(alanine aminotransferase,ALT)值无关(P>0.05),但与血清白蛋白降低相关(P<0.05).结论:CDC25C可能参与了肝病的发生和发展,有望成为HCC诊断和预后监测的重要指标.

AIM： To detect serum antibody against cell division cycle 25 C （CDC25C） in human liver diseases and to evaluate its clinical significance. METHODS： Serum samples were obtained from 61 hepatocellular carcinoma （HCC） patients, 45 liver cirrhosis patients, 61 hepatitis B patients and 61 normal people. Serum antibody to CDC25C was tested by ELISA and the role of CDC25C in liver diseases was analyzed. RESULTS： The positive rate of serum anti- CDC25C antibody in HCC was significantly higher than those in liver cirrhosis, hepatitis B patients and normal people （P 〈 0.05）. The positive rate of serum anti-CDC25C antibody in normal people was significantly lower than those in other groups （P 〈 0.05）, but the difference between liver cirrhosis patients and hepatitis B patients did not reach statistical significance （P 〉 0.05）. Although serum anti-CDC25C antibody in HCC was not significantly associated with age, sex, degree of jaundice or alanine aminotransferase （ALT） （P 〉 0.05）, the positive rate of anti-CDC25C antibody had a significant correlation with decreased serum albumin （P 〈 0.05）. CONCLUSION： CDC25C is associated with progression of liver diseases, and it may bean important indicator for the diagnosis and prognosis monitoring of HCC.